
Jul 13, 2026
Why Is Agilent (NYSE:A) Launching New AI Chromatography Tools?
Modern drug discovery generates vast and heterogeneous datasets — from molecular structures and biological sequences to chromatographic traces and proteomic profiles. Keeping these data streams organised, interpretable, and accessible across functions is one of the core operational challenges facing R&D teams today.
This domain covers the informatics infrastructure that underpins discovery and development work. At the molecular level, that means tools for chemical structure management and computational design. For biological programmes, it includes platforms built around sequence data, antibody characterisation, and biologic registration. Analytical scientists rely on specialised software to acquire and process instrument data — whether from mass spectrometry workflows or chromatography systems — with audit trails that meet regulatory expectations.
Broader still, teams need platforms that unify experiment documentation, assay data, compound tracking, and cross-functional collaboration into coherent workflows. The tools in this domain sit at the intersection of scientific rigour and operational efficiency, reducing the friction between data generation and the decisions that shape research programmes.
Platforms managing the end-to-end lifecycle of biological assays and screening campaigns -- assay registration, compound tracking, results consolidation, and CRO coordination.
Platforms for sequence analysis, biological registration, antibody and protein data management, and multimodal biologics research workflows.
Software for drawing, registering, searching, and computationally designing chemical structures to support medicinal chemistry workflows from ideation through lead optimisation.
Software for acquiring, processing, managing, and reporting data from chromatography instruments (LC, GC, HPLC) and associated analytical platforms, with compliance support.
Software platforms unifying experiment documentation, chemical and biological design, data capture, analytics, and team collaboration across drug discovery and development.
Software for processing and interpreting mass spectrometry and proteomics data to identify, quantify, and characterise proteins, peptides, and biotherapeutics.
Research teams struggle to link compound structures to biological results without a unified informatics infrastructure.
Biologists spend significant time reconciling screening results from multiple sources, formats, and CRO partners.
Chromatography and mass spectrometry outputs remain inaccessible to broader teams when stored in proprietary instrument software.
Managing sequence variants, constructs, and protein data across a biologics programme without structured systems leads to version confusion.
Analytical labs face compliance risk when instrument data acquisition and processing lack complete, tamper-evident records.
Project teams lose visibility into experiment progress when documentation, data, and decisions are spread across disconnected tools.
Chemists use structure–activity relationship tools to guide synthesis priorities when iterating on a lead series.
Research teams process mass spectrometry data to identify and quantify proteins during early target validation studies.
Screening groups track compound plates, assay runs, and results consolidation across multi-week primary screening campaigns.
Analytical teams rely on compliant data systems when generating chromatographic data for regulated method development or QC.
Biologics teams register and compare antibody sequences across discovery campaigns to maintain programme-wide data integrity.
Discovery teams centralise experiment records, data, and decisions on integrated platforms when coordinating across chemistry and biology.




Molecular design workflows depend directly on chemical informatics and structure–activity data managed within this domain.
ELN, LIMS, and inventory systems form the operational layer that feeds data into analytical and informatics platforms.
Omics pipelines generate sequence and expression data that intersects with biologics informatics and proteomics workflows.
PK/PD and safety modelling draws on assay results and molecular data outputs from informatics platforms.
Analytical data from chromatography and biologics characterisation informs process development and manufacturing decisions.

Jul 13, 2026
Why Is Agilent (NYSE:A) Launching New AI Chromatography Tools?

Jul 6, 2026
Why Dotmatics May Be Sitting at the Center of AI's Biggest Untapped Market

Jul 4, 2026
Is Revvity’s Claude Integration Deepening Its Software-Led R&D Strategy Enough To Matter For RVTY?

Jun 25, 2026
Domino Data Lab and Appsilon Partner to Speed AI to Production for Life Sciences

Jun 25, 2026
/C O R R E C T I O N -- Domino Data Lab/

Jun 25, 2026
Nvidia (NVDA) Launches BioNeMo As Life Sciences Firms Roll Out Integrations